Pre-Conference Focus Day: Plasmid DNA Manufacturing

Tuesday, September 26, 2023

7:30 am Registration & Morning Coffee

8:20 am Chair’s Opening Remarks

  • Danny Crawford Director Nucleic Acid Process Sciences, Intellia Therapeutics

Optimizing Plasmid DNA Manufacturing Controls from Fermentation to Purification to Ensure Cost-Effectiveness & Scalability

8:30 am Defining USP Standards for Plasmid DNA as a Starting Material for Cell & Gene Therapy

Synopsis

  • Reporting an overview of the USP general chapter process
  • Describing key quality attributes recommended for plasmids
  • Harnessing best practices for the manufacturing of plasmids and master cell banks

9:00 am Enhancing Plasmid DNA Manufacturing Process Development for mRNA Applications

  • Vivian Chang Associate Director - Upstream Process Development, Ultragenyx Pharmaceutical

Synopsis

  • Advancing fermentation process development
  • Clarifying purification process development
  • Trailblazing process analytics

9:30 am Evolving Strategies for Plasmid Purification

Synopsis

  • Exploring different chromatographic options for the purification of supercoiled plasmid and the linearized plasmid template
  • Evaluating linearization at different levels of plasmid purity
  • Determining the impact of linearized plasmid purity on product quality

10:00 am Morning Break & Networking

Harnessing Cell-Free Synthesis for the Future of Plasmid DNA Manufacturing

10:30 am DNA Templates for mRNA Synthesis

  • Anna Ernst Associate Director DNA Process Development, BioNTech SE

Synopsis

  • Showcasing methods for production of linear DNA
  • Harmonizing regulatory considerations
  • Improving codon optimization

11:00 am Optimized Linear Synthetic DNA as GMP Starting Material to Improve mRNA Production & Delivery Times

Synopsis

  • Improving IVT yield to lower the cost per dosage
  • Developing more accurate and optimized linear DNA templates much faster for advanced therapies
  • Delivering safer starting materials containing only the sequence of interest without any bacterial DNA 

11:30 am Round Table Discussion: Cell-Free vs Traditional Plasmid DNA Production – Establishing the Future of Plasmid Manufacturing to Reduce Costs & Maintain Quality

Synopsis

  • How to establish the best DNA production method to producing step free, large quantities of DNA for multiple transcription reactions
  • How to use the enzymatic method vs high scale, plasmid DNA manufacturing method to eliminate costs and reduce time
  • Discussing the advantages and disadvantages of cell-free synthesis to combat bottlenecks in plasmid DNA production

12:30 pm Lunch Break & Networking

Optimizing Plasmid DNA Production Methods to Improve Speed & Effectiveness for Next Phase mRNA Production

1:30 pm Reviving of a Legacy DNA Vaccine E. coli Plasmid Fermentation Process by Utilizing Single-Use Technology to Support a Modern mRNA Vaccine Program

  • Joshua McNeely Senior Scientist – Vaccines Process Development, Merck & Co

Synopsis

  • Adapting a legacy DNA vaccine that used stainless-steel reactors to develop a novel mRNA vaccine that uses single-use fermenters
  • Overcoming a variety of roadblocks to success including pDNA construct stability, chemical compatibility with single-use fermenter materials, and capability limitations of the existing bioreactors
  • Leveraging thoughtful development and knowledge-sharing to produce sufficient supply of pDNA in AMBR250 and BioBlu 3f SUF bioreactors to fuel IVT development activities

2:00 pm Process & Analytical Control of mRNA Poly A Tails: Challenges & Lessons Learned

2:20 pm Round Table Discussion: Combating the Poly-A Tail Challenge From Plasmid DNA to mRNA Production

Synopsis

  • How to effectively sequence and measure poly A tails from DNA design to mRNA 
  • How to overcome specificity challenges with longer Poly A sequences to ensure translational efficiency

3:20 pm Chair’s Closing Remarks

3:30 pm End of Pre-Conference Focus Day

4:00 pm Private Hosted Site Tour by Curia

Synopsis

For enquiries, please email info@hansonwade.com.